RNA splicing regulation and tumor: A focus on the multifunctional SRSF family as a therapeutic target
Biochemical Pharmacology · 2026-09 · 251 · 118060
DOI: 10.1016/j.bcp.2026.118060 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochemical Pharmacology, 2026-09. Verfasst von Xin Ren und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Jiangyin Clinical College, Xuzhou Medical University, Jiangyin, Jiangsu Province 214400, China. Hauptthemen laut MEDLINE: Neoplasms, Serine-Arginine Splicing Factors, Alternative Splicing, Antineoplastic Agents. Die Arbeit nennt 396 Literaturangaben.
Abstract (Originalsprache)
Alternative splicing (AS) is a crucial mechanism that mediates alterations in protein structure and function, enhances transcript diversity, and regulates post-transcriptional modifications, which is regulated by splicing actors. In a broad range of tumors, aberrant alterations in AS correlate with distinct splice isoforms. Each of these exhibits unique biological activities that facilitate the onset and progression of tumors. Large-scale genomic studies have revealed that splicing actors, primarily acting as pivotal RNA-binding proteins (RBPs), effectively regulate carcinogenic AS progression. This review comprehensively explores the literatures, systematic assessments, structural analyses, regulatory mechanisms, and novel functions of five prominent splicing actor families. Furthermore, recent advancements in pharmacological agents targeting various splicing actors for tumor therapy are summarized. In addition, the article focuses on the twelve members of the serine and arginine-rich splicing factor (SRSF) family because of their substantial role in diverse tumor types. The present study deepens understanding of the intricacies involved in gene expression, yielding innovative insights and methodologies to enhance precision medicine in tumor treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Jiangyin Clinical College, Xuzhou Medical University, Jiangyin, Jiangsu Province 214400, China.
- Department of Medical Records and Medical Insurance Management, Jiangyin Clinical College, Xuzhou Medical University, Jiangyin, Jiangsu Province 214400, China.
- Jiangsu Key Laboratory of Immunity and Metabolism, Xuzhou Medical University, Xuzhou, Jiangsu Province 221004, China; Department of Pathogen Biology and Immunology, School of Basic Medical Sciences, Xuzhou Medical Unive…
- Jiangsu Key Laboratory of Immunity and Metabolism, Xuzhou Medical University, Xuzhou, Jiangsu Province 221004, China; National Demonstration Center for Experimental Basic Medical Science Education (Xuzhou Medical Univer…
- Cancer Institute, Cellular Therapeutics School of Medicine, Xuzhou Medical University, Xuzhou, Jiangsu Province 221002, China. Electronic address: gaoxiaoge@xzhmu.edu.cn.
Zitieren
APA
Ren, X., Shan, W., Salman, M., Ren, J., Gao, X., & Liu, X. (2026). RNA splicing regulation and tumor: A focus on the multifunctional SRSF family as a therapeutic target. Biochemical Pharmacology, 251, 118060. https://doi.org/10.1016/j.bcp.2026.118060
Vancouver
Ren X, Shan W, Salman M, Ren J, Gao X, Liu X. RNA splicing regulation and tumor: A focus on the multifunctional SRSF family as a therapeutic target. Biochemical Pharmacology. 2026;251:118060. doi:10.1016/j.bcp.2026.118060
BibTeX
@article{Ren2026,
author = {Ren, Xin and Shan, Wenhua and Salman, Muhammad and Ren, Jiyuan and Gao, Xiaoge and Liu, Xiangye},
title = {RNA splicing regulation and tumor: A focus on the multifunctional SRSF family as a therapeutic target},
journal = {Biochemical Pharmacology},
year = {2026},
volume = {251},
pages = {118060},
doi = {10.1016/j.bcp.2026.118060}
}
EUVIMED